Arindam Chatterjee

Assistant Professor

achatterjee@ndm.edu 410-532-5042 Bunting Hall (BUN) 206

This profile is currently being updated. Some information may be incomplete.

Biography

Research Scientist– Pfizer, Ann Arbor, MI
Research Scientist – Eli Lilly and Company, Indianapolis, IN
NIH post-doctoral fellow – Vanderbilt University, Nashville, TN (Mentor: Dr. Craig Lindsley)
Research Assistant Professor – St. Louis University, St. Louis, MO
Senior Scientist – Washington University of St. Louis, St. Louis, MO

Education

Ph.D. – Medicinal Chemistry-University of Mississippi, School of Pharmacy, University, MS, US
M.S. – Medicinal Chemistry-University of Mississippi, School of Pharmacy, University, MS, US
B.S. (Honors) – Chemistry –Calcutta University, Calcutta, India
B.Tech. – Pharmaceutical Technology-Calcutta University, Calcutta, India

Research

Interests

Drug discovery, computational chemistry
Neurodegeneration
Oncology
Metabolic syndrome
Dr. Chatterjee’s current research interest focuses on drug-discovery projects related to the development of modulators on Kinase, and Nuclear Hormone receptor targets. We are developing drug molecules to target diseases like Alzheimer’s Disease, Cancer, Obesity, and Type 2 Diabetes. The research involves virtual screening, core medicinal chemistry, structure-activity-relationship, analytical chemistry, and computational chemistry. We utilize these techniques to screen, design, synthesize, and characterize new molecules for the targets.

Publications

Google Scholar,MyNCBI
Current Selected Publications:
“A synthetic ERR agonist alleviates metabolic syndrome”,J. Pharmacol. Expt. Ther.;388(2), 232-243. (2024).DOI:10.1124/jpet.123.001733
"Computational Methods and Tools for Sustainable and Green Approaches in Drug Discovery", inGreen Approaches in Medicinal Chemistry for Sustainable Drug Design, (Second Edition) Banik B.K. Ed.; Vol 2, chapter 27, 603-616, Elsevier, ISBN 978-0-443-16164-3. (2024).DOI10.1016/B978-0-443-16164-3.00024-8
“International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily—Update 2023.Pharmacol. Rev.;75(6), 1233-1318. (2023).DOI10.1124/pharmrev.121.000436
“Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney”,Am. J. Pathol.; 193(12), 1969-1987, (2023).DOI:10.1016/j.ajpath.2023.07.008
“Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915.”Eur. J. of Med. Chem., 258, 115582. DOI10.1016/j.ejmech.2023.115582
“Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity”,ACS Chem. Biol.; 18(4), 756-771, (2023),DOI:10.1021/acschembio.2c00720
“Preparation of substituted purines and naphthyridines as REV-ERB agonists”, WO2022093552, (2022).
“Structural basis of synthetic agonist activation of the nuclear receptor REV-ERB”,Nat. Commun.;13, 7131 (2022),DOI:10.1038/s41467-022-34892-4
“CRTC1/MAML2 directs a PGC-1α-IGF-1 circuit that confers vulnerability to PPARγ inhibition”,Cell Rep.; 34(8), 108768, (2021),DOI:10.1016/j.celrep.2021.108768
“A two-hit model of alcoholic liver disease that exhibits rapid, severe fibrosis”,PLoS One; 16(3), e0249316, (2021),DOI:10.1371/journal.pone.0249316
“LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple-negative breast cancer”,Sci. Rep.; 9(1), 19530, (2019),DOI:10.1038/s41598-019-56038-1
“Preparation of substituted isoquinolines Lxr inverse agonists for the treatment of cancer”, WO2017223514, (2017).
“Identification of C3b-Binding Small-Molecule Complement Inhibitors Using Cheminformatics”,J. Immunol.;198, 3705-3718.(2017)DOI:10.4049/jimmunol.1601932
“Broad anti-tumor activity of a small molecule that selectively targets the Warburg effect and lipogenesis”,Cancer Cell;28, 42-56.(2015). DOI:10.1016/j.ccell.2015.05.007
“Discovery and SAR of muscarinic receptor subtype 1 (M1) allosteric activators from a molecular libraries high throughput screen. Part I: 2,5-dibenzyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones as positive allosteric modulators”,Bioorg. Med. Chem. Let.;25(2), 384-388.(2015). DOI:10.1016/j.bmcl.2014.11.011
“Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screening”,Bioorg. Med. Chem.;22(22), 6409-6421. (2014). DOI:10.1016/j.bmc.2014.09.043

Presentations

Google Scholar
,
MyNCBI
Current Selected Publications
:
“A synthetic ERR agonist alleviates metabolic syndrome”,
J. Pharmacol. Expt. Ther.
;
388(2), 232-243. (
2024
).
DOI:
10.1124/jpet.123.001733
"Computational Methods and Tools for Sustainable and Green Approaches in Drug Discovery", in
Green Approaches in Medicinal Chemistry for Sustainable Drug Design, (Second Edition) Banik B.K. Ed.; Vol 2, chapter 27, 603-616, Elsevier, ISBN 978-0-443-16164-3. (
2024
).
DOI
10.1016/B978-0-443-16164-3.00024-8
“International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily—Update 2023.
Pharmacol. Rev.
;
75
(6), 1233-1318. (
2023
).
DOI
10.1124/pharmrev.121.000436
“
Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney”,
Am. J. Pathol.
; 193(12), 1969-1987, (
2023
).
DOI:
10.1016/j.ajpath.2023.07.008
“Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915.”
Eur. J. of Med. Chem.
, 258, 115582. DOI
10.1016/j.ejmech.2023.115582
“Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity”,
ACS Chem. Biol.
; 18(4), 756-771, (
2023
),
DOI:
10.1021/acschembio.2c00720
“Preparation of substituted purines and naphthyridines as REV-ERB agonists”, WO2022093552, (
2022
).
“Structural basis of synthetic agonist activation of the nuclear receptor REV-ERB”,
Nat. Commun.
;
13
, 7131 (
2022
),
DOI:
10.1038/s41467-022-34892-4
“CRTC1/MAML2 directs a PGC-1α-IGF-1 circuit that confers vulnerability to PPARγ inhibition”,
Cell Rep.
; 34(8), 108768, (
2021
),
DOI:
10.1016/j.celrep.2021.108768
“A two-hit model of alcoholic liver disease that exhibits rapid, severe fibrosis”,
PLoS One
; 16(3), e0249316, (
2021
),
DOI:
10.1371/journal.pone.0249316
“LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple-negative breast cancer”,
Sci. Rep.
; 9(1), 19530, (
2019
),
DOI:
10.1038/s41598-019-56038-1
“Preparation of substituted isoquinolines Lxr inverse agonists for the treatment of cancer”, WO2017223514, (
2017
).
“
Identification of C3b-Binding Small-Molecule Complement Inhibitors Using Cheminformatics
”,
J. Immunol.
;
198
, 3705-3718
.
(
2017
)DOI:
10.4049/jimmunol.1601932
“Broad anti-tumor activity of a small molecule that selectively targets the Warburg effect and lipogenesis”,
Cancer Cell
;
28
, 42-56
.
(
2015
). DOI:
10.1016/j.ccell.2015.05.007
“Discovery and SAR of muscarinic receptor subtype 1 (M1) allosteric activators from a molecular libraries high throughput screen. Part I: 2,5-dibenzyl-2
H
-pyrazolo[4,3-
c
]quinolin-3(5
H
)-ones as positive allosteric modulators”,
Bioorg. Med. Chem. Let.
;
25
(2), 384-388.
(
2015
). DOI:
10.1016/j.bmcl.2014.11.011
“Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screening”,
Bioorg. Med. Chem
.;
22
(22), 6409-6421
. (
2014
). DOI:
10.1016/j.bmc.2014.09.043

Professional Affiliations & Memberships

American Chemical Society
American Association of College of Pharmacy
International Alzheimer’s Association (ISTAART)

Awards

Awarded Intramural CFRD Grant $ 8328.00 for 2024-2025 at NDMU;
Awarded Intramural CFRD Grant $ 6000.00 for 2023-2024 at NDMU